POPIELEC MICHAEL D
Known title: Director, President and CEOCIK: 0001226859
Associated companies
Transaction History
| ULBI | ▲ Buy | Option Exercise | 6,583 | $25K | 12/17/2021 | View on chart |
| ULBI | ▲ Buy | Option Exercise | 6,583 | $25K | 12/17/2021 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Ultralife Upgraded to Neutral on Backlog and Product Progress
Ultralife Corporation received an upgrade to a Neutral rating, driven by its current backlog and progress in commercializing new products. This analyst action suggests improved confidence in the company's operational outlook. The stock is currently trading within its 52-week range, with recent technical signals indicating interaction with key support levels.
Ultralife Upgraded to Neutral on Backlog and Product Progress. Ultralife Corporation received an upgrade to a Neutral rating, driven by its current backlog and progress in commercializing new products. This analyst action suggests improved confidence in the company's operational outlook. The stock is currently trading within its 52-week range, with recent technical signals indicating interaction with key support levels.